Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370601 | 0.90 | TP53 (0.62) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL8538132 | 0.89 | TP53 (0.61) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL13739595 | 0.87 | TP53 (0.74) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL15522001 | 0.85 | TP53 (0.71) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL13740267 | 0.85 | TP53 (0.71) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL21383075 | 0.84 | LMNA (0.48) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL159005 | 0.83 | TP53 (0.69) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL533964 | 0.83 | MAPK1 (0.58) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL13739614 | 0.83 | TP53 (0.69) | TP53MAPK1RAB9AHTR7ADRB2 | |
| SCHEMBL29418129 | 0.83 | TP53 (0.69) | TP53MAPK1RAB9AHTR7ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115216178-B | Ink composition for OLED packaging and preparation method thereof | 西安思摩威新材料有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-116096563-A | Composition for electronic device encapsulation, method for forming electronic device encapsulation film, and electronic device encapsulation film | 柯尼卡美能达株式会社 | 2023-05-09 | — | — | CN | claimed |
| CN-115260834-A | Sulfur-containing high-refractive-index ink composition and preparation method thereof | 西安思摩威新材料有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115216178-A | Ink composition for OLED packaging and preparation method thereof | 西安思摩威新材料有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-107155328-B | Composition for display sealing material and display device containing the same | 三星SDI株式会社 | 2022-05-31 | — | — | CN | claimed |
| US-10700133-B2 | Organic light emitting display | SAMSUNG SDI CO., LTD. (KR) | 2020-06-30 | — | — | US | claimed |
| US-20180158880-A1 | ORGANIC LIGHT EMITTING DISPLAY | SAMSUNG SDI CO., LTD. (KR) | 2018-06-07 | — | — | US | claimed |
| CN-107851730-A | OLED | 三星SDI株式会社 | 2018-03-27 | — | — | CN | claimed |
| CN-107710416-A | Organic light emitting display | 三星SDI株式会社 | 2018-02-16 | — | — | CN | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| US-3980632-A | SYNTHETIC MATERIALS, LEATHER, PAPER, PIGMENTING PLASTICS | SANDOZ LTD. (CH) | 1976-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | TP53 3769/4885MAPK1 2470/4885RAB9A 698/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | TP53 4201/4885MAPK1 2169/4885RAB9A 751/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | TP53 3769/4885MAPK1 2470/4885RAB9A 698/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | TP53 4201/4885MAPK1 2169/4885RAB9A 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.